Pharmafile Logo
Pharmafocus logo
Advanced Search

lung cancer

Showing 15 posts of 192 posts found.

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024
Medical Communications FDA, Oncology, Roche, lung cancer

Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) for the adjuvant treatment following …

News

FDA clears Oryzon’s phase 1/2 trial for lung cancer treatment

April 10, 2024
Research and Development FDA, Oncology, Oryzon, lung cancer

Oryzon Genomics has announced that the US Food and Drug Administration (FDA) has approved its investigational new drug (IND) application …

News

AstraZeneca shares results for Imfinzi in phase 3 trial for small cell lung cancer

April 5, 2024
Research and Development AstraZeneca, Imfinzi, Oncology, clinical trial, lung cancer

AstraZeneca has announced positive high-level results from the phase 3 ADRIATIC trial, which demonstrated that Imfinzi (durvalumab) had a statistically …

News

Merck completes acquisition of Harpoon Therapeutics for $650m

March 12, 2024
Business Services Harpoon Therapeutics, Merck, Oncology, lung cancer

Merck, known as MSD outside of the US and Canada, has announced that it has completed the acquisition of Harpoon …

News

AstraZeneca’s Tagrisso approved by FDA for lung cancer treatment

February 19, 2024
Medical Communications AstraZeneca, Oncology, Tagrisso, lung cancer

AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Tagrisso for the treatment of adult patients …

News

Vergent Bioscience shares phase 2 data for VGT-309

January 29, 2024
Research and Development Oncology, VGT-309, Vergent Bioscience, lung cancer

Vergent Bioscience has announced new data from a phase 2 trial of VGT-309, the company’s investigational tumour-targeted fluorescent imaging agent. …

News

FDA approves BMS’s Augtyro for lung cancer treatment

November 16, 2023
Medical Communications FDA, Oncology, bristol myers squibb, lung cancer

Bristol Myers Squibb has announced that the US Food and Drug Administration (FDA) has approved Augtyro (repotrectinib) for the treatment …

News
lungs

Genentech shares phase 3 results for ALK-positive early-stage lung cancer treatment

September 1, 2023
Research and Development Genentech, NSCLC, Oncology, clinical trials, lung cancer

Roche’s Genentech has announced that the phase 3 ALINA trial assessing Alecensa, compared with platinum-based chemotherapy for the treatment of …

News
az

AstraZeneca’s lung cancer drug gains EU approval

May 28, 2021
Medical Communications AstraZeneca, EU, lung cancer, oncology

AstraZeneca’s Tagrisso (osimertinib) has been approved in the EU for the adjuvant treatment of adult patients with early-stage (IB, II …

News
novartis_window

Novartis’ canakinumab fails to improve lung cancer survival in Phase III study

March 9, 2021
Manufacturing and Production Cancer, Novartis, lung cancer

Novartis has announced that the Phase III CANOPY-2 study evaluating canakinumab, an inhibitor of interleukin-1beta (IL-1β), in combination with the chemotherapy agent …

News

Opdivo scores NICE recommendation in two non-small cell lung cancer indications

September 17, 2020
Sales and Marketing NICE, lung cancer, opdivo

NICE has announced its recommendation of Bristol-Myers Squibb’s blockbuster immunotherapy drug Opdivo (nivolumab) for the treatment of two non-small cell …

News
genentech_web

Genetech scores sixth FDA approval in lung cancer with Gavreto

September 7, 2020
Sales and Marketing Cancer, FDA, Genentech, lung cancer

Genentech’s once-daily oral therapy Gavreto (pralsetinib) has secured FDA backing in the treatment of metastatic rearranged during transfection (RET) fusion-positive …

News

FDA approval for Jazz and PharmaMar’s Zepzelca in metastatic small cell lung cancer

June 17, 2020
Manufacturing and Production, Research and Development, Sales and Marketing Cancer, FDA, PharmaMar, Zepzelca, jazz pharma, lung cancer

The FDA has awarded approval to Jazz Pharma and PharmaMar for Zepzelca (lurbinectedin) as a treatment for metastatic small cell …

News

NICE greenlights Roche’s Rozlytrek for ROS1+ advanced non-small cell lung cancer

June 15, 2020
Sales and Marketing NICE, Roche, Rozlytrek, UK, lung cancer

Roche’s Rozlytrek (entrectinib) has secured recommendation for NHS use in England and Wales after NICE backed the drug in final …

News

NICE reverses previous stance to recommend Roche’s Tecentriq in extensive-stage small-cell lung cancer

May 27, 2020
Research and Development, Sales and Marketing NICE, Roche, lung cancer, tecentriq

NHS patients with treatment-naïve extensive-stage small-cell lung cancer (ES-SCLC) in England and Wales will soon have access to a new …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024